We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.
|Number of pages||4|
|Journal||Multiple Sclerosis and Related Disorders|
|Early online date||16 May 2018|
|Publication status||Published - Aug 2018|